Neurology News

A United Kingdom-based biotech company has announced a global licensing agreement with a California pharma firm to research and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Yoga therapy significantly reduced the felt stigma of epilepsy along with improving anxiety and quality of life at 6 months compared to sham, according to research presented in Neurology.

Neural markers can reliably distinguish mania/hypomania-specific risk from depression-specific risk in young adults, according to a study published in JAMA Psychiatry.

Almost one in five school-aged children and preteens now take melatonin for aid in sleeping, according to survey findings published in JAMA Pediatrics.

PHILADELPHIA — Among patients with advanced HF requiring a left ventricular assist device, measures of cerebrovascular blood flow improved significantly after device implant, a speaker reported.

For older adult males, negative changes in life space were associated with faster cognitive decline and increased risk for neurodegenerative disorders after 7 years, according to research from JAMA Network Open.

Black women in the U.S. who reported experiencing interpersonal racism in employment, housing and police interactions had increased stroke risks, according to findings published in JAMA Network Open.

A precision therapeutics company announced that the first participant has been dosed in a phase 2 clinical trial of a non-dopamine selective modulator to treat those with early-stage Parkinson’s disease.

Neurocrine Biosciences has announced the resolution of litigation resulting from abbreviated new drug applications brought by companies that wished to market a generic version of Ingrezza before its patent expires.

For those with multiple sclerosis, presence of elevated neurofilament light chain biomarkers was associated with symptom progression that predicted clinical disease worsening within 1 to 2 years, according to research from JAMA Neurology.